RxDoctor Payments Data

Jennifer Gwozdz, MD

Family Medicine · Houston, TXNPI 1598702037

Payments from drug & device makers

$4,511in general payments, 2019–2025

Across 92 payments — averaging $49.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$899
  • Lilly USA, LLC$403
  • Abbott$293
  • Boehringer Ingelheim$278
  • Medtronic$144
  • plus $479 from 9 others

What the payments were for

  • Food & beverage$4,47599%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca30$2,015
Novo Nordisk17$899
Lilly USA, LLC13$403
Abbott9$293
Boehringer Ingelheim11$278
Medtronic2$144
GSK2$134
Inspire Medical Systems, Inc.1$123
Cardiovascular Systems Inc.1$116
AbbVie1$30
Exact Sciences1$21
VBI Vaccine (delaware) Inc.1$17
Pfizer1$14
Amgen1$14
Genentech USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,511 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$57,107
Medicare patients
137
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide29$45,401
EliquisApixaban21$24,712
XareltoRivaroxaban19$20,492
JardianceEmpagliflozin13$17,117
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,817
Atorvastatin Calcium270$2,227
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,234
Clobetasol Propionate25$1,006
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril59$974
Amlodipine Besylate160$823
Gemfibrozil28$821
Metformin Hcl123$801
SynthroidLevothyroxine Sodium13$779
Losartan Potassium88$757
Naproxen67$734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$403$45,40129 claims
PfizerEliquis$14$24,71221 claims
Boehringer IngelheimJardiance$278$17,11713 claims
AstraZenecaBreztri Aerosphere$2,015$10,81717 claims
AbbVieSynthroid$30$77913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →